Introduction {#Sec1}
============

Heart failure (HF) remains the most common reason for hospital admission in the elderly \[[@CR1]--[@CR4]\]. Although improvements in re-admission rates have been recently observed, outcomes for patients admitted for HF remain poor, with high post-discharge mortality and rehospitalization rates \[[@CR2]--[@CR7]\].

Atrial fibrillation (AFib) is a common comorbid state in HF patients, including those admitted for acute HF \[[@CR8]\]. Acute HF registries report a prevalence of AFib ranging between 27 and 45% \[[@CR2]\]. There is a bidirectional pathogenetic relationship linking HF with AFib \[[@CR9]\]. On one hand, HF leads to increased atrial pressures and neurohormonal activation, resulting in structural and electrical atrial remodeling: factors that constitute the ideal substrate for the development of AFib \[[@CR10], [@CR11]\]. On the other hand, AFib doubles the risk for HF development. It is a frequent trigger for HF decompensation resulting in a high overall risk of cardiovascular complications, including a fivefold higher risk of stroke \[[@CR2], [@CR12]\]. The presence of AFib directly affects the outcomes of HF patients, predicting a worse prognosis \[[@CR13]\].

Serelaxin, a recombinant form of human relaxin-2, improves symptoms and outcomes in patients admitted for acute HF, as reported by the RELAX-AHF trial \[[@CR14]--[@CR18]\]. In this study, 53% of patients had a history of AFib, while 41% had AFib on screening electrocardiogram performed on admission \[[@CR19], [@CR20]\]. A previously published sub-group analysis showed no differential effects of seralaxin based on the presence or absence of a history of AFib or AFib at screening on key study end points \[[@CR19]\]. In the present study, we sought to expand our knowledge on the efficacy and safety of serelaxin in acute HF patients with and without AFib at the time of presentation by addressing all pre-specified efficacy and safety end points, adverse events and biomarkers of organ damage. We further analyzed the clinical profile of patients with AFib as well as the independent prognostic significance of AFib on patient outcomes.

Methods {#Sec2}
=======

The design and primary results of the RELAX-AHF trial are described in detail elsewhere \[[@CR21]\]. Briefly, the study randomized 1161 AHF patients to 48-h intravenous infusion of serelaxin (30 μg/kg/day, *n* = 581) or placebo (*n* = 580) within 16 h from presentation. The study was approved by the institutional review boards and all subjects enrolled gave informed consent.

In the present analysis, we compared the effects of serelaxin versus placebo on pre-specified efficacy end points, safety end points, and biomarkers indicative of organ damage, in patients with and without AFib. The presence of AFib was defined as evidence of either atrial fibrillation or atrial flutter on the screening electrocardiogram performed on admission.

The trial's primary efficacy end points were dyspnea improvement, defined as the area under the curve of dyspnea change from baseline on a 100-mm visual analog scale (VAS-AUC) through day 5 and the presence of moderately or markedly better breathing compared to baseline reported on a 7-point Likert scale at 6, 12 and 24 h. Adverse events (AEs) were collected through day 5, serious AEs through day 14, rehospitalizations through day 60, and vital status through day 180. Rehospitalizations and deaths were adjudicated by an independent, blinded committee. The trial's secondary efficacy end points included cardiovascular death or rehospitalization for heart or renal failure and days alive and out of hospital through day 60. Cardiovascular death through day 180 was pre-specified as an additional efficacy end point, and all-cause death through day 180 was a pre-specified safety end point. Stroke through day 180 was defined to include any AE of stroke (through day 14), any rehospitalization for stroke (through day 60), or death due to stroke (through day 180). Biomarkers indicative of congestion and/or organ damage, including high-sensitivity troponin T (hs-TnT), N-terminal beta-type natriuretic pro-peptide (NT-proBNP), cystatin C, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and growth differentiation factor-15 (GDF-15) were assessed serially using a central core laboratory.

Statistical analysis {#Sec3}
--------------------

Baseline characteristics were compared between patients with and without AFib, without imputation for missing values, using two-sample *t* test for continuous variables and Chi square or Fisher's exact test for categorical variables. Estimates of the serelaxin treatment effect (odds ratios, mean differences, or hazard ratios) for patients with and without AFib and an interaction test were obtained from separate regression models (logistic regression, analysis of covariance, or Cox proportional hazards). For the analyses of outcomes in patients with and without AFib and the analyses of treatment effects, two subjects with unknown AFib status were imputed as without AFib. Missing baseline covariates were also imputed as the mean for continuous variables or as the mode for categorical variables within the treatment group. Missing biomarker values were not imputed. Analyses were conducted on an intention-to-treat basis. All *p* values were two sided, and values \<0.05 were considered to be statistically significant. Analyses were performed using SAS© release 9.2 (SAS Institute, Cary, NC, USA).

Results {#Sec4}
=======

Baseline characteristics in patients with and without AFib {#Sec5}
----------------------------------------------------------

From a total 1161 patients who underwent a screening electrocardiogram on admission, 479 patients had AFib (41.3%). In addition, 602 (51.9%) patients reported a history of AFib, although this was not used as a criterion for the present analysis. Patients with AFib were significantly older with a different race and geographic distribution than those without AFib (Table [1](#Tab1){ref-type="table"}). Patients with AFib were less likely to have an ischemic etiology of HF or a reduced ejection fraction (HFrEF), but similar New York Heart Association (NYHA) class distribution when compared to patients without AFib. AFib patients had a higher resting heart rate than non-AFib patients, but similar systolic blood pressure. Symptoms and signs of congestion did not differ between the two groups with the exception of peripheral edema, which was more frequent in patients with AFib. Several comorbid conditions including hyperlipidemia, diabetes mellitus, smoking, history of myocardial infarction and depression were less frequent in patients with AFib. A history of hypertension, lung disease and cerebrovascular or peripheral arterial disease did not differ between the two groups. Regarding cardiovascular therapies, patients with AFib were more frequently prescribed beta-blockers and digoxin, and had more frequently undergone a pacemaker implantation. However, they were less likely to have a cardiac defibrillator or a biventricular pacing system. With respect to baseline laboratory findings, renal, liver function and natriuretic peptides did not differ between the two groups. Patients with AFib, however, had lower troponin T and higher GDF-15 levels.

Table 1Comparison of baseline characteristics between patients with and without atrial fibrillation (AFib) on admissionBaseline characteristicAFib, *n* = 479^a^No AFib, *n* = 680^a^*p* value^b^Demographics Age (years)74.6 (9.5)70.2 (12.0)\<0.0001 Male284 (59.3)440 (64.7)0.0608 White/Caucasian466 (97.3)628 (92.4)0.0003 Geographic region\<0.0001  Eastern Europe266 (55.5)295 (43.4)  Western Europe89 (18.6)115 (16.9)  South America26 (5.4)45 (6.6)  North America23 (4.8)90 (13.2)  Israel75 (15.7)135 (19.9)Heart failure characteristics Left ventricular EF40.3 (14.5)37.5 (14.5)0.0015 EF \< 40%217 (48.9)380 (58.9)0.0011 Ischemic heart disease226 (47.2)376 (55.3)0.0065 Time from presentation to randomization (h)7.6 (4.6)8.1 (4.7)0.0768 CHF 1 month prior362 (75.6)497 (73.1)0.3414 NYHA class 30 days before admission0.1274  I128 (26.8)195 (29.0)  II115 (24.1)187 (27.8)  III180 (37.7)209 (31.1)  IV54 (11.3)81 (12.1)Clinical signs Body mass index, kg/m^2^29.3 (5.3)29.2 (6.0)0.7501 Syst. blood pressure, mmHg141.5 (16.2)142.6 (16.8)0.2523 Diast. blood pressure, mmHg80.6 (13.8)77.9 (14.5)0.0018 Heart rate, beat per minute83.0 (15.9)77.3 (13.8)\<0.0001 Respiratory rate, breaths per minute21.9 (4.7)21.9 (4.6)0.8515 HF hospitalization past year161 (33.6)235 (34.6)0.7378Congestion at baseline Edema395 (83.0)513 (75.9)0.0037 Orthopnea459 (96.4)645 (95.4)0.3962 Jugular vein distension359 (76.7)489 (74.5)0.4054 Dyspnea on exertion469 (99.8)665 (99.6)0.6468 Dyspnea by VAS43.7 (20.5)44.5 (19.6)0.4915 Rales453 (95.2)640 (94.5)0.6336Comorbidities Hypertension417 (87.1)587 (86.3)0.7181 Hyperlipidemia223 (46.6)392 (57.6)0.0002 Diabetes mellitus196 (40.9)353 (51.9)0.0002 Cigarette smoking35 (7.3)118 (17.4)\<0.0001 Stroke or other cerebrovascular event66 (13.8)91 (13.4)0.8460 Peripheral vascular disease62 (12.9)93 (13.7)0.7181 Asthma, bronchitis, or COPD77 (16.1)106 (15.6)0.8229 History of Atrial fibrillation or flutter454 (94.8)148 (21.8)\<0.0001 History of CRT or ICD procedures112 (23.4)182 (26.8)0.1925 Myocardial infarction141 (50.5)262 (60.0)0.0132 Depression14 (2.9)46 (6.8)0.0036Medication ACE inhibitor244 (50.9)388 (57.1)0.0394 ACEi or ARBs314 (65.6)472 (69.4)0.1662 Angiotensin-receptor blocker83 (17.3)101 (14.9)0.2563 Beta-blocker344 (71.8)448 (65.9)0.0325 Aldosterone antagonist166 (34.7)199 (29.3)0.0517 Oral loop diuretic 30 days prior42.3 (59.9)46.4 (68.7)0.2900 Digoxin152 (31.7)76 (11.2)\<0.0001 Nitrates at randomization31 (6.5)50 (7.4)0.5623Devices Pacemaker66 (13.8)55 (8.1)0.0018 Implantable cardiac defibrillator42 (8.8)112 (16.5)0.0001 Biventricular pacing33 (6.9)80 (11.8)0.0059Baseline laboratory findings Hemoglobin, g/dL12.83 (1.71)12.77 (1.95)0.5721 White blood cell count, ×10^9^/L7.909 (2.723)8.370 (2.916)0.0082 Lymphocyte, %18.15 (7.27)18.18 (8.19)0.9433 Glucose, mmol/L7.29 (3.01)8.07 (3.89)0.0002 BUN, mmol/L9.80 (4.03)9.75 (4.03)0.8340 Creatinine, umol/L114.3 (31.5)118.1 (34.2)0.0621 Cystatin C, mg/L1.47 (1.43, 1.51)1.44 (1.41, 1.47)0.2294 eGFR, mL/min per 1.73 m^2^53.20 (12.98)53.72 (13.06)0.5097 Sodium, mmol/L141.0 (3.8)140.7 (3.4)0.3074 Potassium, mmol/L4.27 (0.63)4.27 (0.64)0.9697 Calcium, mmol/L2.26 (0.14)2.27 (0.16)0.5059 Alanine aminotransferase, U/L (log transformed)23.4 (22.2, 24.7)23.7 (22.5, 24.9)0.7569 Albumin, g/L40.41 (3.93)40.11 (4.59)0.2407 Total cholesterol, mmol/L3.94 (1.07)4.20 (1.22)0.0001 CRP, mg/L (log transformed)8.56 (7.57, 9.68)8.49 (7.73, 9.31)0.9101 Uric acid, umol/L478.4 (132.3)473.8 (138.2)0.5751 NT-proBNP, ng/L (log transformed)5279 (4919, 5665)4905 (4553, 5284)0.1599 Troponin T, ug/L (log transformed)0.031 (0.028, 0.033)0.038 (0.036, 0.041)\<0.0001 GDF-15, ng/L (log transformed)4598 (4329, 4883)4167 (3953 4392)0.0165^a^Mean (SD), or geometric mean (95% CI) if log transformed, presented for continuous variables, and *n* (%) for categorical variables (% based on the total number of patients with a non-missing value of the end point)^b^ *p* value was based on *t* test (with Satterthwaite correction if unequal variances), Chi-square test, or Fisher's exact test

Efficacy and safety of serelaxin in patients with and without atrial fibrillation {#Sec6}
---------------------------------------------------------------------------------

Atrial fibrillation was present in 233 of 580 (40.2%) patients in the serelaxin arm and in 246 of 579 (42.5%) patients in the placebo arm (*p* = 0.424). Most of the study end points did not differ significantly between patients with and without AFib after multivariable adjustment, but AFib patients had a significantly higher incidence of cardiovascular mortality at 180 days (adjusted *p* = 0.0173, Table [2](#Tab2){ref-type="table"}).

Table 2Outcomes in patients with and without atrial fibrillationClinical end pointsAFib, *n* = 479\
Estimate^a^No AFib, *n* = 682\
Estimate^a,b^Unadjusted effect of AFib (yes versus no)Adjusted effect of AFib (yes versus no)(95% CI)*p* value^c^(95% CI)*p* value^c,d^Dyspnea improvement by VAS to day 5, mm-h2222.58 (1962.77, 2482.39)2749.22 (2538.24, 2960.20)−526.64 (−858.50, −194.78)0.0019−166.06 (−570.24, 238.11)0.4207Dyspnea improvement by Likert scale at 6, 12 and 24 h110/479 (23.0%)196/682 (28.7%)0.74 (0.56, 0.97)0.0282----Worsening heart failure (WHF)53/479 (11.1%)57/682 (8.4%)1.34 (0.92, 1.96)0.12581.13 (0.67, 1.91)0.6446Hospitalization length, days11.82 (10.80, 12.84)8.82 (8.26, 9.37)3.00 (1.92, 4.08)\<0.0001----Cardiovascular death or HF/RF hospitalization through day 6069/479 (14.5%)82/682 (12.1%)1.21 (0.88, 1.67)0.24141.13 (0.81, 1.59)0.4739All-cause death through day 18051/479 (10.7%)56/682 (8.3%)1.33 (0.91, 1.95)0.13721.46 (0.98, 2.18)0.0651Cardiovascular mortality to day 18043/479 (9.1%)45/682 (6.7%)1.40 (0.92, 2.12)0.11701.71 (1.10, 2.67)0.0173Stroke through day 18013/479 (2.8%)5/682 (0.8%)3.77 (1.34, 10.58)0.0116----^a^Mean (95% CI), *n* (K-M %) and *n* (%) are presented for continuous outcome, survival outcome and binary outcome, respectively^b^Two subjects with unknown AFib status were imputed as without AFib (treatment-specific mode)^**c**^Treatment effect represents mean difference (from linear regression analysis), hazard ratio (from Cox proportional hazards model) and odds ratio (from logistic regression analysis) for continuous outcome, survival outcome and binary outcome, respectively^d^Dyspnea VAS AUC to day 5 is adjusted for age, US-like, weight, dyspnea on exertion, hypertension, mitral regurgitation, history of atrial fibrillation or flutter, alkaline phosphatase, sodium, body temperature (linear spline at Q1), log2 troponin (linear spline at Q2), dyspnea by VAS (cubic), uric acid (cubic); WHF is adjusted for white race, height (linear spline at 173), diastolic BP(linear spline at 70), heart rate (trichotomized: \<73, \[73, 85), ≥85), respiratory rate, dyspnea by VAS, mm (cubic), coronary artery bypass graft, hyperthyroidism, total bilirubin, total cholesterol, albumin, troponin (log2 transformed, linear spline at −4.2); CV death or HF/RF rehospitalization through day 60 is adjusted for white race, NYHA class 30 days before systolic BP, respiratory rate, number of HF hospitalizations past year, orthopnea (ordinal), asthma or bronchitis or COPD, hyperthyroidism, lymphocytes %, BUN, phosphate (cubic), sodium, total protein (linear spline at 68); CV mortality through day 180 is adjusted for the following variables: US-like, systolic BP, orthopnea (ordinal), angina, hyperthyroidism, mitral regurgitation, atrial fibrillation/flutter at screening, white blood cell count, lymphocytes %, BUN, sodium, potassium, calcium, total protein, log2 troponin, log2 NT-proBNP. All-cause death to day 180 is adjusted for age, CHF 1 month previously, stroke or other cerebrovascular events, respiratory rate, systolic BP, edema (2/3 versus 0/1), orthopnea (2/3 versus 0/1), lymphocytes (%), sodium, creatinine and log2 troponin

The effect of serelaxin versus placebo on several study end points in patients with and without AFib is outlined in Table [3](#Tab3){ref-type="table"}. There was no differential effect of serelaxin on dyspnea relief according to VAS scale up to day 5 (interaction *p* = 0.5954; Table [3](#Tab3){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}) or by Likert scale at 6, 12 and 24 h (Table [3](#Tab3){ref-type="table"}) Serelaxin induced a similar reduction in the incidence of worsening HF (interaction *p* = 0.7423) irrespective of the presence or absence of AFib. Similarly, the length of hospital stay did not differ (interaction *p* = 0.3837). Cardiovascular death or hospitalization for HF or renal failure through day 60 and all-cause death and cardiovascular mortality at 180 days were neither significantly affected by serelaxin in either of the two group interaction (interaction *p* = 0.1583, 0.0643 and 0.1472, respectively; Fig. [2](#Fig2){ref-type="fig"}).

Table 3Treatment effect (serelaxin versus placebo) on various outcomes in patients with and without atrial fibrillation (AFib)OutcomeAFib, *n* = 479No AFib, *n* = 682^c^Interaction *p* value^d^Serelaxin, *n* = 233^a^Placebo, *n* = 246^a^Treatment effect (95% CI)\
*p* value^b^Serelaxin, *n* = 348^a^Placebo, *n* = 334^a^Treatment, effect (95% CI)\
*p* value^b^Dyspnea improvement by VAS-AUC to day 5, mm-h^e^2500.48 (2165.85, 2835.11)1959.37 (1565.60, 2353.13)541.11 (33.79, 1048.44)\
0.03662926.41 (2654.92, 3197.90)2564.61 (2239.43, 2889.79)361.80 (−63.30, 786.90)\
0.09530.5954Dyspnea improvement by Likert scale at 6, 12 and 24 h55 (23.6%)55 (22.4%)1.07 (0.70, 1.64)\
0.7457101 (29.0%)95 (28.4%)1.03 (0.74, 1.43)\
0.86710.8784Worsening heart failure19 (8.2%)34 (13.8%)0.57 (0.32, 1.00)\
0.050620 (5.8%)37 (11.1%)0.50 (0.29, 0.86)\
0.01260.7423Hospitalization length, days11.12 (9.77, 12.48)12.48 (10.96, 13.99)−1.35 (−3.00, 0.30)\
0.10858.62 (7.79, 9.45)9.02 (8.28, 9.76)−0.39 (−1.78, 0.99)\
0.57610.3837Cardiovascular death or HF/RF hospitalization through day 60^e^30 (13.0%)39 (16.0%)0.80 (0.49, 1.28)\
0.348646 (13.4%)36 (10.9%)1.27 (0.82, 1.96)\
0.28660.1583All-cause death through day 18015 (6.5%)36 (14.8%)0.42 (0.23, 0.77)\
0.005127 (7.9%)29 (8.7%)0.90 (0.53, 1.52)\
0.68880.0643Cardiovascular mortality through day 180^e^13 (5.6%)30 (12.4%)0.44 (0.23, 0.85)\
0.013921 (6.1%)24 (7.3%)0.84 (0.47, 1.52)\
0.57130.1472Stroke through day 1803 (1.30%)10 (4.23%)0.31 (0.09, 1.13)\
0.07594 (1.16%)1 (0.32%)3.88 (0.43, 34.71)\
0.22550.0518^a^Mean (95% CI) presented for continuous outcome, *n* (K-M %) for survival outcomes, *n* (%) for binary outcomes^b^Treatment effect represents the mean difference estimated from linear regression models for continuous outcomes, the hazard ratio from Cox regression for time-to-event outcomes, and the odds ratio from logistic regression for binary outcomes^c^Two subjects with unknown AFib status were imputed as without AFib (treatment-specific mode)^d^Interaction *p* value is based on test of treatment by AF interaction from linear regression, Cox or logistic regression model as appropriate^e^Result presented in \[[@CR19]\]

Fig. 1Patient-reported dyspnea change (serelaxin versus placebo) in patients with and without atrial fibrillation (AF), according to visual analog scale from baseline to day 5

Fig. 2Kaplan--Meier curves (serelaxin versus placebo) for cardiovascular death through day 180 (*upper panel*) and all-cause death through day 180 (*lower panel*) in patients with and without atrial fibrillation (AF)

Stroke through 180 days occurred in 13 patients with AFib (2.8%) and 5 patients without AFib (0.8%, *p* = 0.0116). There was a trend for a lower incidence of stroke in the serelaxin arm in patients with AFib \[hazard ratio serelaxin versus placebo, 0.31 (0.09, 1.13) in AFib versus 3.88 (0.43, 34.71) in patients without AFib, interaction *p* = 0.0518\].

The effect of serelaxin versus placebo on AEs in patients with and without AFib is shown in Table [4](#Tab4){ref-type="table"}. The overall incidence of serious AEs did not differ based on the presence or absence of AFib (interaction *p* = 0.3905). The same applied to the incidence of AEs indicative of hypotension or renal or hepatic impairment. It should be noted that there was no difference in anticoagulation use at baseline and from baseline through day 14 and day 60 among the study groups. In addition, CHA~2~DS~2~-VASc score was similar among the study groups (Table [5](#Tab5){ref-type="table"}).

Table 4Treatment effect (serelaxin versus placebo) on adverse events (AE) in patients with and without atrial fibrillation (AFib)Adverse eventAFib, *n* = 479No AFib, *n* = 680Interaction *p* valueSerelaxin, *n* = 233Placebo, *n* = 246Oddsratio(95% CI)\
*p* valueSerelaxin, *n* = 347Placebo, *n* = 333Odds ratio (95% CI)\
*p* valuePatients with any serious AE through day 1426 (11.16%)45 (18.29%)0.56 (0.32, 0.97)\
0.029343 (12.39%)51 (15.32%)0.78 (0.49, 1.24)\
0.31720.3905Patients with AE indicative of hypotension through day 14^a^10 (4.29%)9 (3.66%)1.18 (0.42, 3.35)\
0.816618 (5.19%)18 (5.41%)0.96 (0.46, 1.99)\
1.00000.7769Patients with AE indicative of renal impairment through day 14^b^4 (1.72%)12 (4.88%)0.34 (0.08, 1.15)\
0.073713 (3.75%)20 (6.01%)0.61 (0.27, 1.31)\
0.21160.5189Patients with AE indicative of hepatic impairment through day 14^c^1 (0.43%)7 (2.85%)0.15 (0.00, 1.16)\
0.06882 (0.58%)4 (1.20%)0.48 (0.04, 3.36)\
0.44220.5491*AE* adverse events^a^Blood pressure decreased, dizziness, loss of consciousness, hypotension, orthostatic hypotension, presyncope, somnolence or syncope^b^Azotemia, blood creatinine increase, oliguria, proteinuria, renal failure, acute renal failure or renal impairment^c^Blood bilirubin increase, cholestasis, hepatic congestion, hepatic cyst, hepatic steatosis, hyperbilirubinemia, hypoalbuminemia, INR increase or liver disorder

Table 5Comparison of anticoagulation therapy and CHADS2-VASc score among study groupsAFib, *n* = 479No AFib, *n* = 680Interaction *p* valueSerelaxin, *n* = 233Placebo, *n* = 246Treatment effect95% CI*p* valueSerelaxin*n* = 347Placebo*n* = 333Treatment effect95% CI*p* valueAnticoagulant use at baseline^a^119 (51.1)136 (55.3)0.84(0.59, 1.21)0.356090 (25.9)102 (30.6)0.79(0.57, 1.11)0.17440.8028Anticoagulant use through day 14^a^157 (67.4)179 (72.8)0.77(0.52, 1.14)0.1987115 (33.1)122 (36.6)0.86(0.63, 1.18)0.33910.6878Anticoagulant use through day 60^a^165 (70.8)186 (75.6)0.78(0.52, 1.17)0.2364124 (35.7)132 (39.6)0.85(0.62, 1.16)0.29360.7630CHADS~2~-VASc score at baseline^b^4.41 (4.20, 4.61)4.59 (4.41, 4.77)−0.18(−0.47, 0.11)0.21714.26 (4.08, 4.44)4.37 (4.19, 4.54)−0.10(−0.35, 0.14)0.39930.6863Mean (95% CI) and *n* (%) are presented for continuous outcome and binary outcome, respectively^a^Treatment effect represents odds ratio (from logistic regression analysis). Each model includes the subgroup variable (AFib versus No AFib), treatment and treatment by subgroup interaction as covariates^b^Treatment effect represents mean difference (from linear regression analysis). Each model includes the subgroup variable (AFib versus No AFib), treatment and treatment by subgroup interaction as covariates. Two patients had missing AFib values at screening. Anticoagulants include acenocoumarol, dalteparin, enoxaparin, fondaparinux, heparin, heparin-fraction, nadraparin, phenprocoumon, tinzaparin, warfarin

Effects of serelaxin on biomarkers of organ damage in patients with and without atrial fibrillation {#Sec7}
---------------------------------------------------------------------------------------------------

The effects of serelaxin versus placebo on biomarkers of organ damage were similar irrespective of AFib presence at baseline (Table [6](#Tab6){ref-type="table"}; all interaction *p* levels were nonsignificant). There was a less pronounced increase in cystatin C with serelaxin than with placebo treatment in both AFib groups, while creatinine decreased in the serelaxin group and increased in the placebo group. There were greater reductions in NT-proBNP, AST, ALT, and GDF-15 at 48 h in the serelaxin group than in the placebo group, both in patients with and without AFib. Serelaxin induced similar reductions in relative changes in troponin T; however, in patients with AFib troponin T increased in the placebo group and remained the same in the serelaxin group, while in patients without AFib troponin T stayed the same in placebo patients and decreased in serelaxin patients.

Table 6Effect of treatment (serelaxin versus placebo) on biomarkers of organ damage in patients with and without atrial fibrillation (AFib)BiomarkerAFib, *n* = 479No AFib, *n* = 682^c^Interaction *p* value^d^Serelaxin, *n* = 233^a^Placebo, *n* = 246^a^Treatment effect (95% CI)\
*p* value^b^Serelaxin, *n* = 348^a^Placebo, *n* = 334^a^Treatment effect (95% CI)\
*p* value^b^Change to day 2 in cystatin C (log2 transformed)1.01 (0.99, 1.04)1.08 (1.06, 1.11)0.93 (0.90, 0.96)\
\<0.00011.04 (1.02, 1.06)1.08 (1.05, 1.10)0.96 (0.94, 0.99)\
0.00710.1512Change to day 2 in creatinine−4.90 (−7.95, −1.85)5.34 (2.55, 8.13)−10.25 (−14.78, −5.72)\
\<0.0001−2.17 (−5.09, 0.75)6.68 (3.85, 9.50)−8.84 (−12.65, −5.04)\
\<0.00010.6424Change to day 2 in troponin (log2 transformed)1.00 (0.95, 1.06)1.08 (1.03, 1.13)0.93 (0.85, 1.01)\
0.08230.94 (0.89, 0.99)1.00 (0.95, 1.06)0.94 (0.87, 1.01)\
0.08810.8281Change to day 2 in NT-proBNP (log2 transformed)0.54 (0.49, 0.58)0.70 (0.65, 0.76)0.76 (0.68, 0.86)\
\<0.00010.46 (0.43, 0.50)0.54 (0.50, 0.59)0.85 (0.77, 0.94)\
0.00190.1459Change to day 2 in GDF 15 (log2 transformed)0.77 (0.72, 0.82)0.93 (0.88, 0.99)0.82 (0.75, 0.90)\
\<0.00010.80 (0.76, 0.85)0.88 (0.84, 0.93)0.91 (0.84, 0.98)\
0.00910.0941Change to day 2 in ALT (log2 transformed)0.83 (0.80, 0.86)0.91 (0.86, 0.96)0.92 (0.87, 0.97)\
0.00220.82 (0.80, 0.85)0.87 (0.85, 0.90)0.94 (0.90, 0.99)\
0.01150.4777Change to day 2 in AST (log2 transformed)0.84 (0.80, 0.87)0.91 (0.86, 0.96)0.92 (0.86, 0.98)\
0.00880.78 (0.76, 0.81)0.87 (0.84, 0.90)0.90 (0.85, 0.95)\
\<0.00010.5810*cTNT* cardiac troponin-T, *NT-proBNP* N-terminal B-type natriuretic pro-peptide, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase^a^Mean (95% CI) change from baseline to day 2 or geometric mean (95% CI) − the ratio of day 2 to baseline − if log2 transformed^b^Treatment effect represents mean difference or the ratio of the relative changes if log2 transformed^c^Two subjects with unknown AFib status were imputed as without AFib (treatment-specific mode)^d^Interaction *p* value based on test of treatment by AF interaction from linear regression

Atrial fibrillation during follow-up {#Sec8}
------------------------------------

Atrial fibrillation or flutter was reported in 13 patients by day 14; the incidence was similar in the serelaxin (*n* = 7) and placebo (*n* = 6) groups. Ten patients, seven in the serelaxin group and three in the placebo group, were rehospitalized for AFib through day 60. In patients without AFib at baseline screening, there were eight episodes of AFib or flutter through day 14, including five (1.44%) in the serelaxin group and three (0.90%) in the placebo group \[OR, 1.61, 95% CI (0.31, 10.4), *p* = 0.725\].

Discussion {#Sec9}
==========

A 48-h serelaxin infusion in patients with acute HF improved dyspnea and congestion, reduced early HF worsening and hospital stay and improved long-term outcome in terms of cardiovascular and all-cause mortality at 6 months \[[@CR14]\]. The effects of serelaxin versus placebo on dyspnea relief to day 5, cardiovascular death or rehospitalizations for heart or renal failure at 60 days or all-cause or cardiovascular mortality at 180 days were further shown to be generally consistent across several patient subgroups, including a history of AFib and AFIb on admission \[[@CR17]\]. In the present analysis, we expanded those results by addressing the interaction between treatment assignment (serelaxin or placebo) and the presence or absence of AFib on admission on all efficacy and safety end points, including dyspnea improvement at 6, 12 and 24 h, worsening HF, hospitalization length, all-cause and cardiovascular death at 180 days and incidence of stroke over the same time period.

Patients with AFib on admission enrolled in the RELAX-AHF trial differed in HF etiology and phenotype as well as in baseline comorbidities compared to patients without AFib. In addition, AFIb patients had a higher adjusted incidence of cardiovascular mortality at 180 days. However, dyspnea response to therapy, HF worsening and cardiovascular death or hospitalization for HF or renal failure through day 60 as well as all-cause death through day 180 were similar in the two subgroups after multivariable adjustment. This finding suggests that worse outcomes observed in acute HF patients with AFib may be partly influenced by the different profile of those patients rather than being wholly attributable to the arrhythmia per se.

Serelaxin was similarly safe in the two groups in terms of serious adverse events or events indicative of hypotension, or renal or hepatic impairment. Not only was serelaxin safe, but it also seemed to provide organ protection, as the previously documented beneficial effect of serelaxin on biomarkers of organ damage was consistent in patients with and without AFib. In addition, although the incidence of stroke was, as expected, higher in patients with AFib, interestingly serelaxin tended to reduce its incidence in those particular patients.

Atrial fibrillation is known to confer a fivefold increase in the risk of stroke \[[@CR12]\]. Studies have shown that even subclinical AFib episodes as short as 6 min or perioperative AFib in patients undergoing non-cardiac surgery are followed by an increased long-term risk of stroke \[[@CR22]--[@CR25]\]. Stroke may be a devastating condition associated with significant morbidity and mortality. The present post hoc analysis, despite the rather short follow-up period, confirmed a higher risk of stroke in AFib patients. Interestingly, serelaxin was followed by a lower incidence of stroke in those patients compared to placebo. Relaxin is a known vasoactive peptide that modifies beneficially arterial resistance and compliance. Regarding the cerebral vasculature, in particular, relaxin seems to have specific beneficial effects that have led to the hypothesis that it may play a protective role against ischemic stroke \[[@CR26]\]. Experimental studies have shown that relaxin pretreatment reduced infarct size after middle cerebral artery occlusions in rats, an action accomplished through the activation of the relaxin family peptide receptor 3 (RXFP3), a process that also involved activation of the endothelial nitric oxide synthase (eNOS) pathway \[[@CR27]--[@CR29]\]. Those effects within the cerebral vascular bed may lead to vasodilation and improved brain tissue perfusion. In a small clinical study in 36 patients recovering from stroke, relaxin plus rehabilitation induced a greater recovery compared to rehabilitation alone at 20 and 40 days as indicated by measures of physical activity, cognitive function and global function \[[@CR26]\]. It should be stressed however that the incidence rate of stroke was low and therefore those results should be interpreted with caution.

Besides its vasodilatatory and anti-ischemic actions discussed earlier, relaxin seems to possess anti-inflamatory and antifibrotic properties \[[@CR30]\]. As inflammation and fibrosis are thought to be important aspects in the pathophysiology of AFib, it has been postulated that relaxin may have a role in the management of AFib \[[@CR31]\]. In an experimental study in hypertensive rats, relaxin suppressed AFib triggered by programmed stimulation \[[@CR32]\]. The suppression of AFib was achieved by increasing conduction velocity from a combination of reversal of atrial fibrosis and hypertrophy and by increasing Na^+^ current density \[[@CR32]\]. In RELAX-AHF, the occurrence of AFib during follow-up was not systematically recorded; there were only a few spontaneous reports of AFib as an adverse event. As a result, the effects of the drug on the occurrence of AFib could not be assessed, but this may be the aim of a future study.

The results of the present study should be cautiously treated as they are derived by a post hoc subgroup analysis of a randomized trial. In addition, the main RELAX-AHF study was not primarily designed and powered to assess medium and long-term prognostic outcomes and therefore the corresponding findings should be carefully interpreted.

In conclusion, serelaxin was overall similarly safe and efficacious in improving short- and long-term clinical outcomes and inducing organ protection in acute HF patients with and without AFib. However, prospective trials are required to confirm those findings.

An erratum to this article is available at <https://doi.org/10.1007/s00392-017-1139-5>.
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